Niraparib

Niraparib

SCHEMBL1421875

NC(=O)c1cccc2cn(-c3ccc([C@@H]4CCCNC4)cc3)nc12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

PARP1PARP2

The experimentally established mechanism targets of Niraparib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 known ✓ P09874 20/20 1.00
PARP2 known ✓ Q9UGN5 11/20 1.00
PARP3 Q9Y6F1 10/20 1.00
TNKS O95271 1/20 1.00
CHRM2 P08172 1/20 1.00
CHRM1 P11229 1/20 1.00
SLC6A2 P23975 1/20 1.00
SLC6A4 P31645 1/20 1.00
ADRA1A P35348 1/20 1.00
SLC6A3 Q01959 1/20 1.00
KCNH2 Q12809 1/20 1.00
DYRK1A Q13627 1/20 1.00
PARP15 Q460N3 1/20 1.00
PARP14 Q460N5 1/20 1.00
PARP10 Q53GL7 1/20 1.00
PARP12 Q9H0J9 1/20 1.00
TNKS2 Q9H2K2 1/20 1.00
PARP4 Q9UKK3 1/20 1.00
DYRK1B Q9Y463 1/20 1.00
HRH3 Q9Y5N1 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Niraparib SCHEMBL1422151 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1421952 1.00 PARP1 (1.00) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL1422061 0.99 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL567839 0.99 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL28370623 0.99 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL567840 0.99 PARP1 (0.98) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL3737274 0.96 PARP1 (0.92) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL3737277 0.96 PARP1 (0.92) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL3740349 0.95 PARP1 (0.91) PARP1PARP2PARP3TNKSCHRM2
Niraparib SCHEMBL3659848 0.94 PARP1 (0.89) PARP1PARP2PARP3TNKSCHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 7679 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4048809-B1 SYSTEMS AND METHODS FOR PREDICTING THERAPEUTIC SENSITIVITY TEMPUS AI INC (US) 2026-05-27 EP claimed
US-12637510-B2 Oncolytic virus compositions and methods for the treatment of cancer CITY OF HOPE (US) 2026-05-26 US claimed
CN-122075716-A Medicine for treating tumor by combining recombinant oncolytic virus and small-molecule anticancer medicine 2026-05-26 CN claimed
WO-2026105121-A1 ANTICANCER FORMULATIONS AND USES THEREOF INTRAGEL THERAPEUTICS LTD. (IL) 2026-05-21 WO claimed
WO-2026106998-A1 PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA)-TARGETED POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR AND RELATED COMPOSITION AND METHOD OF USE PURDUE RESEARCH FOUNDATION (US) 2026-05-21 WO claimed
US-20260137700-A1 PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE SK BIOPHARMACEUTICALS CO LTD (KR) 2026-05-21 US claimed
WO-2026106315-A1 METHOD FOR PROVIDING INFORMATION ON ATM GENE FUNCTION 연세대학교 산학협력단 2026-05-21 WO claimed
WO-2026104998-A1 SUBSTITUTED IMIDAZOPYRIDINE COMPOUND DERIVATIVES AND THEIR PHARMACEUTICAL USE AVELOS THERAPEUTICS INC. (KR) 2026-05-21 WO claimed
EP-4743497-A2 COMPOSITIONS AND METHODS RELATED TO TUMOR ACTIVATED ANTIBODIES TARGETING PSMA AND EFFECTOR CELL ANTIGENS Janux Therapeutics, Inc. (US) 2026-05-20 EP claimed
EP-4744665-A1 COMBINATION OF POLQ INHIBITOR COMPOUND AND ANTI-CANCER THERAPEUTIC AGENT OR RADIOTHERAPY Simcere Zaiming Pharmaceutical Co., Ltd. (CN) 2026-05-20 EP claimed
WO-2017042634-A2 USE OF DIANHYDROGALACTITOL OR DERIVATIVES AND ANALOGS THEREOF FOR TREATMENT OF NON-SMALL-CELL LUNG CARCINOMA, GLIOBLASTOMA, AND OVARIAN CARCINOMA BY INDUCTION OF DNA DAMAGE AND STALLING OF CELL CYCLE DEL MAR PHARMACEUTICALS (CA) 2017-03-16 WO claimed
EP-2805945-A1 Amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors MSD Italia S.r.l. (IT) 2014-11-26 EP claimed
CN-101578279-B Amide substituted indazoles as poly (ADP ribose) polymerase (PARP) inhibitors ANGELETTI P IST RICHERCHE BIO 2013-07-17 CN claimed
US-8071623-B2 Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide INSTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA 2011-12-06 US claimed
EP-2336120-A1 Combinations containing amide substituted indazoles as poly(ADP-ribose)polymerase (PARP) inhibitors Istituto di ricerche di Biologia Molecolare P. Angeletti S.R.L. (IT) 2011-06-22 EP claimed
WO-2011058367-A2 DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR ASTRAZENECA AB (SE) 2011-05-19 WO claimed
EP-2109608-B1 AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ANGELETTI P IST RICHERCHE BIO (IT) 2011-03-23 EP claimed
EP-2109608-A1 AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. (IT) 2009-10-21 EP claimed
WO-2008084261-A1 AMIDE SUBSTITUTED INDAZOLES AS POLY(ADP-RIBOSE)POLYMERASE (PARP) INHIBITORS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) 2008-07-17 WO claimed
US-20080167345-A1 Anticancer, antiinflammatory, antitumor agents, diabetes, neurodegenerative diseases, retroviral infection, retinal damage or skin senescence and UV-induced skin damage; protecting against the toxicity of chemotherapy; 2-(4-Piperidin-3-ylphenyl)2H-indazole-7-carboxamide MERCK SHARP & DOHME LLC 2008-07-10 US claimed